IP Library Granted Patent US 10,639,383
Granted Patent B2
US 10,639,383 · App. 15/357,772 · Granted May 5, 2020

Methods and compositions for engineering immunity

Inventors: Michael C. Holmes (Richmond, CA); Brigit E. Riley (Richmond, CA)
Assignee: Sangamo Therapeutics, Inc.
A61K48/0058A61K35/12A61K35/28A61P25/16A61P35/00C07K16/18C07K16/30C07K16/32C12N15/62C12N15/86A01K2227/105A01K2267/03A61K2039/505C07K2317/622C07K2317/626C07K2319/31C12N2750/14143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,639,383
App. No.
15/357,772
Granted
May 5, 2020
Kind
B2
Abstract

Nucleases and methods of using these nucleases for expressing an antibody from a safe harbor locus in a secretory tissue, and clones and animals derived therefrom.

Claims (8)

1. A method of expressing, in a mammalian liver cell, an antibody, wherein the antibody binds to a protein expressed in the brain, wherein the protein is selected from the group consisting of a cancer antigen, a cellular receptor, a cytokine, a growth factor, a growth factor receptor, a kinase inhibitor, an integrin, α-synuclein, an amyloid protein, and a complement protein, the method comprising,

administering to the liver cell (i) an adeno-associated viral (AAV) vector comprising a transgene encoding the antibody, wherein the antibody is a single chain fragment variable (ScFv), an intrabody or a diabody and (ii) one or more AAV vectors comprising sequences encoding a pair of zinc finger nucleases that cleave an endogenous albumin gene in the liver cell, such that the transgene is integrated into the liver cell and the liver cell produces and secretes the antibody such that the antibody is taken up by neurons in the brain.

2. The method of claim 1 , wherein expression of the transgene is driven by the endogenous albumin promoter.

3. The method of claim 1 , wherein the transgene is a fusion protein comprising amino acids encoded by the transgene and by the endogenous albumin gene.

4. The method of claim 1 , wherein the antibody is expressed in the serum and/or brain of the subject.

5. The method of claim 1 , wherein the AAV vector is an AAV2 vector.

6. The method of claim 5 , wherein the AAV2 vector is an AAV2/6 or AAV2/8 vector.

7. A genetically modified liver cell produced by the method of claim 1 .

Assignments (2)
CHANGE OF NAME Recorded Jan 13, 2020
From: SANGAMO BIOSCIENCES, INC.
To: SANGAMO THERAPEUTICS, INC.
Reel/Frame 051579/0811 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2017
From: HOLMES, MICHAEL C.; RILEY, BRIGIT E.
To: SANGAMO BIOSCIENCES, INC.
Reel/Frame 041647/0877 →
Continuity (3)
Provisional Application 62405521 · Oct 7, 2016
Provisional Application 62258864 · Nov 23, 2015
Related Publication 20170196992A1 · Jul 13, 2017
Cited By (1)
US 12,214,023